Novo obesity drug could launch in U.S. end 2014
COPENHAGEN (Reuters) - Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential. Full story

